Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Premarin
      • 1.3.3 Vagifem
      • 1.3.4 Estrace
      • 1.3.5 Estring
      • 1.3.6 Femring
    • 1.4 Market Segment by Application
      • 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application (2019-2025)
      • 1.4.2 Vaginal Gels
      • 1.4.3 Creams
      • 1.4.4 Tablets
      • 1.4.5 Rings
      • 1.4.6 Patches
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size
      • 2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2014-2025
      • 2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2014-2025
    • 2.2 Postmenopausal Vaginal Atrophy Drugs Growth Rate by Regions
      • 2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
      • 3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
    • 3.6 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Premarin Sales and Revenue (2014-2019)
      • 4.1.2 Vagifem Sales and Revenue (2014-2019)
      • 4.1.3 Estrace Sales and Revenue (2014-2019)
      • 4.1.4 Estring Sales and Revenue (2014-2019)
      • 4.1.5 Femring Sales and Revenue (2014-2019)
    • 4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type
    • 4.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type
    • 4.4 Postmenopausal Vaginal Atrophy Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application

    6 United States

    • 6.1 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
    • 6.2 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
    • 6.3 United States Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
    • 7.2 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
    • 7.3 European Union Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application

    8 China

    • 8.1 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
    • 8.2 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
    • 8.3 China Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Company
    • 9.2 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
    • 9.3 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
    • 9.4 Rest of World Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Postmenopausal Vaginal Atrophy Drugs Sales by Countries
      • 9.4.2 Rest of World Postmenopausal Vaginal Atrophy Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Actavis plc
      • 10.1.1 Actavis plc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.1.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.1.5 Actavis plc Recent Development
    • 10.2 Bionovo, Inc.
      • 10.2.1 Bionovo, Inc. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.2.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.2.5 Bionovo, Inc. Recent Development
    • 10.3 Endoceutics, Inc.
      • 10.3.1 Endoceutics, Inc. Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.3.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.3.5 Endoceutics, Inc. Recent Development
    • 10.4 Novo Nordisk A/S
      • 10.4.1 Novo Nordisk A/S Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.4.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.4.5 Novo Nordisk A/S Recent Development
    • 10.5 Pfizer Inc.
      • 10.5.1 Pfizer Inc. Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.5.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.5.5 Pfizer Inc. Recent Development
    • 10.6 Teva Pharmaceuticals Ltd.
      • 10.6.1 Teva Pharmaceuticals Ltd. Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.6.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.6.5 Teva Pharmaceuticals Ltd. Recent Development
    • 10.7 Therapeutics MD, Inc.
      • 10.7.1 Therapeutics MD, Inc. Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.7.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.7.5 Therapeutics MD, Inc. Recent Development
    • 10.8 Shionogi & Company
      • 10.8.1 Shionogi & Company Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.8.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.8.5 Shionogi & Company Recent Development
    • 10.9 Allergan plc
      • 10.9.1 Allergan plc Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.9.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.9.5 Allergan plc Recent Development
    • 10.10 Shionogi & Co. Ltd.
      • 10.10.1 Shionogi & Co. Ltd. Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Postmenopausal Vaginal Atrophy Drugs
      • 10.10.4 Postmenopausal Vaginal Atrophy Drugs Product Introduction
      • 10.10.5 Shionogi & Co. Ltd. Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels
      • 11.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
    • 11.3 Postmenopausal Vaginal Atrophy Drugs Customers

    12 Market Forecast

    • 12.1 Global Postmenopausal Vaginal Atrophy Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type
    • 12.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application
    • 12.4 Postmenopausal Vaginal Atrophy Drugs Forecast by Regions
      • 12.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
      In 2019, the market size of Postmenopausal Vaginal Atrophy Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Postmenopausal Vaginal Atrophy Drugs.

      This report studies the global market size of Postmenopausal Vaginal Atrophy Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Postmenopausal Vaginal Atrophy Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Actavis plc
      Bionovo, Inc.
      Endoceutics, Inc.
      Novo Nordisk A/S
      Pfizer Inc.
      Teva Pharmaceuticals Ltd.
      Therapeutics MD, Inc.
      Shionogi & Company
      Allergan plc
      Shionogi & Co. Ltd.

      Market Segment by Product Type
      Premarin
      Vagifem
      Estrace
      Estring
      Femring

      Market Segment by Application
      Vaginal Gels
      Creams
      Tablets
      Rings
      Patches

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Postmenopausal Vaginal Atrophy Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Postmenopausal Vaginal Atrophy Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Postmenopausal Vaginal Atrophy Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now